152 related articles for article (PubMed ID: 12821248)
1. Blockade of atrial angiotensin II type 1 receptors: a novel antiarrhythmic strategy to prevent atrial fibrillation?
Klein HU; Goette A
J Am Coll Cardiol; 2003 Jun; 41(12):2205-6. PubMed ID: 12821248
[No Abstract] [Full Text] [Related]
2. Effects of angiotensin II type 1 receptor antagonist on electrical and structural remodeling in atrial fibrillation.
Kumagai K; Nakashima H; Urata H; Gondo N; Arakawa K; Saku K
J Am Coll Cardiol; 2003 Jun; 41(12):2197-204. PubMed ID: 12821247
[TBL] [Abstract][Full Text] [Related]
3. Angiotensin II antagonist prevents electrical remodeling in atrial fibrillation.
Nakashima H; Kumagai K; Urata H; Gondo N; Ideishi M; Arakawa K
Circulation; 2000 Jun; 101(22):2612-7. PubMed ID: 10840013
[TBL] [Abstract][Full Text] [Related]
4. Blockade of the renin angiotensin system in heart failure: the potential place of angiotensin II receptor blockers.
van Veldhuisen DJ; Voors AA
Eur Heart J; 2000 Jan; 21(1):14-6. PubMed ID: 10610738
[No Abstract] [Full Text] [Related]
5. [Drug therapies following heart failure and myocardial infarction(discussion)].
Shimizu T; Komuro I; Hirayama H; Hiramitsu S; Shimizu K; Yoshida O
Nihon Rinsho; 2002 Jun; 60(6):1235-50. PubMed ID: 12143782
[No Abstract] [Full Text] [Related]
6. [Angiotensin-II receptor blockers].
Metelitsa VI
Ter Arkh; 1996; 68(8):64-7. PubMed ID: 9019837
[No Abstract] [Full Text] [Related]
7. Angiotensin II type 1 receptor blockers.
Burnier M
Circulation; 2001 Feb; 103(6):904-12. PubMed ID: 11171802
[No Abstract] [Full Text] [Related]
8. Role of the renin-angiotensin-aldosterone system in atrial fibrillation and cardiac remodeling.
Healey JS; Morillo CA; Connolly SJ
Curr Opin Cardiol; 2005 Jan; 20(1):31-7. PubMed ID: 15596957
[TBL] [Abstract][Full Text] [Related]
9. Multiple actions of angiotensin II in hypertension: benefits of AT1 receptor blockade.
Schiffrin EL; Touyz RM
J Am Coll Cardiol; 2003 Sep; 42(5):911-3. PubMed ID: 12957442
[No Abstract] [Full Text] [Related]
10. Modulation of the renin-angiotensin pathway through enzyme inhibition and specific receptor blockade in pacing-induced heart failure: I. Effects on left ventricular performance and neurohormonal systems.
Spinale FG; de Gasparo M; Whitebread S; Hebbar L; Clair MJ; Melton DM; Krombach RS; Mukherjee R; Iannini JP; O SJ
Circulation; 1997 Oct; 96(7):2385-96. PubMed ID: 9337215
[TBL] [Abstract][Full Text] [Related]
11. Autoregulated glomerular filtration rate during candesartan treatment in hypertensive type 2 diabetic patients.
Mansour G; Mansour J
Curr Hypertens Rep; 2002 Dec; 4(6):437-8. PubMed ID: 12419171
[No Abstract] [Full Text] [Related]
12. [Organ protection by angiotensin II receptor blockers].
Kumagai H; Onami T; Takimoto C; Iigaya K; Saruta T
Nihon Rinsho; 2004 Mar; 62 Suppl 3():569-73. PubMed ID: 15171437
[No Abstract] [Full Text] [Related]
13. [The Diabetic Retinopathy Candesartan Trials (DIRECT) programme].
Ohashi H; Takagi H
Nihon Rinsho; 2005 Jun; 63 Suppl 6():297-301. PubMed ID: 15999723
[No Abstract] [Full Text] [Related]
14. Angiotensin and cerebral blood flow.
Saavedra JM; Nishimura Y
Cell Mol Neurobiol; 1999 Oct; 19(5):553-73. PubMed ID: 10384255
[No Abstract] [Full Text] [Related]
15. Effects of angiotensin receptor blockade on atrial electrical remodelling and the 'second factor' in a goat burst-paced model of atrial fibrillation.
Hall MC; Kirubakaran S; Choudhury R; Abidin N; Peters NS; Garratt CJ
J Renin Angiotensin Aldosterone Syst; 2010 Dec; 11(4):222-33. PubMed ID: 20507873
[TBL] [Abstract][Full Text] [Related]
16. Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program.
Ducharme A; Swedberg K; Pfeffer MA; Cohen-Solal A; Granger CB; Maggioni AP; Michelson EL; McMurray JJ; Olsson L; Rouleau JL; Young JB; Olofsson B; Puu M; Yusuf S;
Am Heart J; 2006 Jul; 152(1):86-92. PubMed ID: 16838426
[TBL] [Abstract][Full Text] [Related]
17. Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: assessment of Reduction in Mortality and morbidity (CHARM) program.
Ducharme A; Swedberg K; Pfeffer MA; Cohen-Solal A; Granger CB; Maggioni AP; Michelson EL; McMurray JJ; Olsson L; Rouleau JL; Young JB; Yusuf S
Am Heart J; 2006 May; 151(5):985-91. PubMed ID: 16644318
[TBL] [Abstract][Full Text] [Related]
18. Changeover Trial of Azilsartan and Olmesartan Comparing Effects on the Renin-Angiotensin-Aldosterone System in Patients with Essential Hypertension after Cardiac Surgery (CHAOS Study).
Sezai A; Osaka S; Yaoita H; Arimoto M; Hata H; Shiono M; Sakino H
Ann Thorac Cardiovasc Surg; 2016 Jun; 22(3):161-7. PubMed ID: 27086671
[TBL] [Abstract][Full Text] [Related]
19. [Angiotensin II receptor antagonists].
Naka T
Tanpakushitsu Kakusan Koso; 2000 Apr; 45(6 Suppl):956-60. PubMed ID: 10771657
[No Abstract] [Full Text] [Related]
20. [Pharma-clinics. The drug of the month. Candesartan (Atacand)].
Kulbertus H
Rev Med Liege; 1999 Jun; 54(6):557-60. PubMed ID: 10446528
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
